A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study

Abstract Background Treatment switching in randomised controlled trials (RCTs) is a problem for health technology assessment when substantial proportions of patients switch onto effective treatments that would not be available in standard clinical practice. Often statistical methods are used to adju...

Full description

Bibliographic Details
Main Authors: Nicholas R Latimer, Alice Dewdney, Marco Campioni
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Medical Research Methodology
Subjects:
Online Access:https://doi.org/10.1186/s12874-024-02140-6
_version_ 1797276447997427712
author Nicholas R Latimer
Alice Dewdney
Marco Campioni
author_facet Nicholas R Latimer
Alice Dewdney
Marco Campioni
author_sort Nicholas R Latimer
collection DOAJ
description Abstract Background Treatment switching in randomised controlled trials (RCTs) is a problem for health technology assessment when substantial proportions of patients switch onto effective treatments that would not be available in standard clinical practice. Often statistical methods are used to adjust for switching: these can be applied in different ways, and performance has been assessed in simulation studies, but not in real-world case studies. We assessed the performance of adjustment methods described in National Institute for Health and Care Excellence Decision Support Unit Technical Support Document 16, applying them to an RCT comparing panitumumab to best supportive care (BSC) in colorectal cancer, in which 76% of patients randomised to BSC switched onto panitumumab. The RCT resulted in intention-to-treat hazard ratios (HR) for overall survival (OS) of 1.00 (95% confidence interval [CI] 0.82–1.22) for all patients, and 0.99 (95% CI 0.75–1.29) for patients with wild-type KRAS (Kirsten rat sarcoma virus). Methods We tested several applications of inverse probability of censoring weights (IPCW), rank preserving structural failure time models (RPSFTM) and simple and complex two-stage estimation (TSE) to estimate treatment effects that would have been observed if BSC patients had not switched onto panitumumab. To assess the performance of these analyses we ascertained the true effectiveness of panitumumab based on: (i) subsequent RCTs of panitumumab that disallowed treatment switching; (ii) studies of cetuximab that disallowed treatment switching, (iii) analyses demonstrating that only patients with wild-type KRAS benefit from panitumumab. These sources suggest the true OS HR for panitumumab is 0.76–0.77 (95% CI 0.60–0.98) for all patients, and 0.55–0.73 (95% CI 0.41–0.93) for patients with wild-type KRAS. Results Some applications of IPCW and TSE provided treatment effect estimates that closely matched the point-estimates and CIs of the expected truths. However, other applications produced estimates towards the boundaries of the expected truths, with some TSE applications producing estimates that lay outside the expected true confidence intervals. The RPSFTM performed relatively poorly, with all applications providing treatment effect estimates close to 1, often with extremely wide confidence intervals. Conclusions Adjustment analyses may provide unreliable results. How each method is applied must be scrutinised to assess reliability.
first_indexed 2024-03-07T15:28:22Z
format Article
id doaj.art-08464f6ea30a43ceb22ea46f3c857e49
institution Directory Open Access Journal
issn 1471-2288
language English
last_indexed 2024-03-07T15:28:22Z
publishDate 2024-01-01
publisher BMC
record_format Article
series BMC Medical Research Methodology
spelling doaj.art-08464f6ea30a43ceb22ea46f3c857e492024-03-05T16:33:32ZengBMCBMC Medical Research Methodology1471-22882024-01-0124111310.1186/s12874-024-02140-6A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case studyNicholas R Latimer0Alice Dewdney1Marco Campioni2Sheffield Centre for Health and Related Research (SCHARR), University of SheffieldWeston Park Cancer Centre, Sheffield Teaching HospitalAmgen (Europe) GmbHAbstract Background Treatment switching in randomised controlled trials (RCTs) is a problem for health technology assessment when substantial proportions of patients switch onto effective treatments that would not be available in standard clinical practice. Often statistical methods are used to adjust for switching: these can be applied in different ways, and performance has been assessed in simulation studies, but not in real-world case studies. We assessed the performance of adjustment methods described in National Institute for Health and Care Excellence Decision Support Unit Technical Support Document 16, applying them to an RCT comparing panitumumab to best supportive care (BSC) in colorectal cancer, in which 76% of patients randomised to BSC switched onto panitumumab. The RCT resulted in intention-to-treat hazard ratios (HR) for overall survival (OS) of 1.00 (95% confidence interval [CI] 0.82–1.22) for all patients, and 0.99 (95% CI 0.75–1.29) for patients with wild-type KRAS (Kirsten rat sarcoma virus). Methods We tested several applications of inverse probability of censoring weights (IPCW), rank preserving structural failure time models (RPSFTM) and simple and complex two-stage estimation (TSE) to estimate treatment effects that would have been observed if BSC patients had not switched onto panitumumab. To assess the performance of these analyses we ascertained the true effectiveness of panitumumab based on: (i) subsequent RCTs of panitumumab that disallowed treatment switching; (ii) studies of cetuximab that disallowed treatment switching, (iii) analyses demonstrating that only patients with wild-type KRAS benefit from panitumumab. These sources suggest the true OS HR for panitumumab is 0.76–0.77 (95% CI 0.60–0.98) for all patients, and 0.55–0.73 (95% CI 0.41–0.93) for patients with wild-type KRAS. Results Some applications of IPCW and TSE provided treatment effect estimates that closely matched the point-estimates and CIs of the expected truths. However, other applications produced estimates towards the boundaries of the expected truths, with some TSE applications producing estimates that lay outside the expected true confidence intervals. The RPSFTM performed relatively poorly, with all applications providing treatment effect estimates close to 1, often with extremely wide confidence intervals. Conclusions Adjustment analyses may provide unreliable results. How each method is applied must be scrutinised to assess reliability.https://doi.org/10.1186/s12874-024-02140-6Treatment switchingTreatment crossoverSurvival analysisCancerInverse probability weightingRank preserving structural failure time model
spellingShingle Nicholas R Latimer
Alice Dewdney
Marco Campioni
A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study
BMC Medical Research Methodology
Treatment switching
Treatment crossover
Survival analysis
Cancer
Inverse probability weighting
Rank preserving structural failure time model
title A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study
title_full A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study
title_fullStr A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study
title_full_unstemmed A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study
title_short A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study
title_sort cautionary tale an evaluation of the performance of treatment switching adjustment methods in a real world case study
topic Treatment switching
Treatment crossover
Survival analysis
Cancer
Inverse probability weighting
Rank preserving structural failure time model
url https://doi.org/10.1186/s12874-024-02140-6
work_keys_str_mv AT nicholasrlatimer acautionarytaleanevaluationoftheperformanceoftreatmentswitchingadjustmentmethodsinarealworldcasestudy
AT alicedewdney acautionarytaleanevaluationoftheperformanceoftreatmentswitchingadjustmentmethodsinarealworldcasestudy
AT marcocampioni acautionarytaleanevaluationoftheperformanceoftreatmentswitchingadjustmentmethodsinarealworldcasestudy
AT nicholasrlatimer cautionarytaleanevaluationoftheperformanceoftreatmentswitchingadjustmentmethodsinarealworldcasestudy
AT alicedewdney cautionarytaleanevaluationoftheperformanceoftreatmentswitchingadjustmentmethodsinarealworldcasestudy
AT marcocampioni cautionarytaleanevaluationoftheperformanceoftreatmentswitchingadjustmentmethodsinarealworldcasestudy